Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, PR China.
PLoS One. 2013 Aug 2;8(8):e70340. doi: 10.1371/journal.pone.0070340. Print 2013.
The aim of this study was to present the therapeutic outcome of patients with locally advanced pancreatic cancer treated with pancreatoduodenectomy combined with vascular resection and reconstruction in addition to highlighting the mortality/morbidity and main prognostic factors associated with this treatment.
We retrospectively analyzed the clinical and pathological data of a total of 566 pancreatic cancer patients who were treated with PD from five teaching hospitals during the period of December 2006-December 2011. This study included 119 (21.0%) patients treated with PD combined with vascular resection and reconstruction. We performed a detailed statistical analysis of various factors, including postoperative complications, operative mortality, survival rate, operative time, pathological type, and lymph node metastasis.
The median survival time of the 119 cases that received PD combined with vascular resection was 13.3 months, and the 1-, 2-, and 3-year survival rates were 30.3%, 14.1%, and 8.1%, respectively. The postoperative complication incidence was 23.5%, and the mortality rate was 6.7%. For the combined vascular resection group, complications occurred in 28 cases (23.5%). For the group without vascular resection, complications occurred in 37 cases (8.2%). There was significant difference between the two groups (p = 0.001). The degree of tumor differentiation and the occurrence of complications after surgery were independent prognostic factors that determined the patients' long-term survival.
Compared with PD without vascular resection, PD combined with vascular resection and reconstruction increased the incidence of postoperative complications. However, PD combined with vascular resection and reconstruction could achieve the complete removal of tumors without significantly increasing the mortality rate, and the median survival time was higher than that of patients who underwent palliative treatment. In addition, the two independent factors affecting the postoperative survival time were the degree of tumor differentiation and the presence or absence of postoperative complications.
本研究旨在展示接受胰十二指肠切除术(PD)联合血管切除和重建治疗的局部晚期胰腺癌患者的治疗结果,并强调这种治疗方法的死亡率/发病率和主要预后因素。
我们回顾性分析了 2006 年 12 月至 2011 年 12 月期间,5 所教学医院的 566 例胰腺癌患者的临床和病理资料。本研究包括 119 例接受 PD 联合血管切除和重建治疗的患者。我们对各种因素进行了详细的统计分析,包括术后并发症、手术死亡率、生存率、手术时间、病理类型和淋巴结转移。
接受 PD 联合血管切除的 119 例患者的中位生存时间为 13.3 个月,1、2 和 3 年生存率分别为 30.3%、14.1%和 8.1%。术后并发症发生率为 23.5%,死亡率为 6.7%。联合血管切除组发生并发症 28 例(23.5%),未行血管切除组发生并发症 37 例(8.2%),两组差异有统计学意义(p=0.001)。肿瘤分化程度和术后并发症的发生是影响患者长期生存的独立预后因素。
与未行血管切除的 PD 相比,PD 联合血管切除和重建增加了术后并发症的发生率。然而,PD 联合血管切除和重建可以在不显著增加死亡率的情况下实现肿瘤的完全切除,且中位生存时间高于姑息治疗患者。此外,影响术后生存时间的两个独立因素是肿瘤分化程度和术后并发症的有无。